From PharmaLive News Archive - Sep 17, 2007
Johnson and Johnson and FDA informed healthcare professionals that
the WARNINGS section of the prescribing information for haloperidol
has been revised to include a new Cardiovascular subsection regarding
cases of sudden death, QT prolongation and Torsades de Pointes(TdP)
in patients treated with haloperidol, especially when given
intravenously, or at doses higher than recommended.
www.peoplewho.org